Optimal use of granulocyte-colony-stimulating factor in patients with cancer 1who are at risk for chemotherapy-induced neutropenia
Cappozzo C (2004) Optimal use of granulocyte-colony-stimulating factor in patients with cancer 1who are at risk for chemotherapy-induced neutropenia. Oncol Nurs Forum 31(3):569-576
In vitro and in vivo assays for high-molecular-weight pegylated muteins of granulocyte colony-stimulating factor
De Ley M (ed). Humana, Totowa, NJ
Eliason J, Tare N, Bowen S, Inoue T, Horii I (2003) In vitro and in vivo assays for high-molecular-weight pegylated muteins of granulocyte colony-stimulating factor. In: De Ley M (ed) Cytokine protocols. Methods in molecular biology. Humana, Totowa, NJ, pp 167-176
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy
Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C et al (2003) PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol 21(7):1398-1403
(2003)J Clin Oncol, vol.21, Issue.7, pp. 1398-1403
Adolescents with cancer: Experience of life and how it could be made easier
Hokkanen H, Eriksson E, Ahonen O, Salantera S (2004) Adolescents with cancer: experience of life and how it could be made easier. Cancer Nurs 27(4):325-335
Adverse prognostic features in 251 children treated for acute myeloid leukemia
Hurwitz CA, Schell MJ, Pui CH, Crist WM, Behm F, Mirro J Jr (1993) Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Pediatr Oncol 21(1):1-7